|1.||Wun, Ted: 2 articles (05/2014 - 04/2007)|
|2.||White, Richard H: 2 articles (05/2014 - 04/2007)|
|3.||Chew, Helen: 2 articles (05/2014 - 04/2007)|
|4.||Quinones-Hinojosa, Alfredo: 2 articles (03/2013 - 10/2003)|
|5.||Lamborn, Kathleen R: 2 articles (05/2009 - 10/2003)|
|6.||Dicato, Mario: 2 articles (01/2009 - 01/2008)|
|7.||Dranitsaris, George: 2 articles (01/2009 - 01/2006)|
|8.||Pabinger, I: 2 articles (05/2005 - 09/2004)|
|9.||Tafur, A J: 1 article (12/2015)|
|10.||Harris, P J: 1 article (12/2015)|
09/01/2012 - "The incidence of VTE was significantly greater in patients with malignancy (52% vs 10%; P = .001), and 88% of all VTEs in this series were diagnosed in patients with cancer. "
01/01/2013 - "Randomised controlled trials (RCTs) and controlled clinical trials (CCTs) comparing systemic treatments to prevent venous thrombo-embolic events (VTEs) in paediatric cancer patients with tunnelled CVCs with a control intervention or no systemic treatment. "
10/09/2012 - "We therefore conducted a study to evaluate the occurrence of asymptomatic VTEs of the lower limbs in ambulatory cancer patients to further evaluate the association of these asymptomatic VTEs on survival during a 9-month follow-up period. "
12/01/2015 - "Venous thromboembolic events (VTEs) are a significant cause of death in patients with cancer. "
01/01/2015 - "Relative incidence rate of VTEs in cancer patients (12 months after diagnosis) versus non-cancer cases (12 months after index date) was calculated using multivariable Cox proportional hazard models. "
04/01/2007 - "Fifty-eight percent had multiple VTEs and 7% had a radiologically confirmed pulmonary embolism. "
04/27/2005 - "To calculate the overall negative likelihood ratio (NLR) of a VTE after a negative or inconclusive chest CT scan for pulmonary embolism, we included VTEs that were objectively confirmed by an additional imaging test despite a negative or inconclusive CT scan and objectively confirmed VTEs that occurred during clinical follow-up of at least 3 months. "
04/27/2005 - "Two reviewers independently abstracted patient demographics, frequency of venous thromboembolic events (VTEs), CT modality (single-slice CT, multidetector-row CT, or electron-beam CT), false-negative results, and deaths attributable to pulmonary embolism. "
05/01/2014 - "The primary outcome of our study was all incident VTEs, including deep vein thrombosis and pulmonary embolism. "
11/01/2015 - "Among these patients, 43 cases of VTEs (35 deep venous thromboses [DVTs], 5 pulmonary embolisms [PEs], and 3 DVTs that progressed to PEs) occurred, resulting in an incidence of 0.30% (95% confidence interval [CI], 0.22% to 0.41%) for DVT, 0.06% (95% CI, 0.03% to 0.12%) for PE, and 0.34% (95% CI, 0.25% to 0.46%) for VTEs overall. "
06/01/2003 - "Among 85 children, 29 (34%) had VTE; 28 VTEs appeared in the upper venous system, and 1 was sinovenous thrombosis. "
03/01/2015 - "The purpose of this study is to examine the association between TXA on complications such as venous thromboembolic events (VTEs) and flap-related thrombosis in combat trauma patients undergoing tissue transfer for extremity reconstruction. "
06/01/2012 - "Pharmaceutical thrombosis prophylaxis (PTP) with low-molecular-weight heparin (LMWH) is highly effective in preventing venous thromboembolic events (VTEs) and fatal pulmonary embolism. "
12/01/2005 - "Daily low-dose aspirin (81 mg orally) given to patients with newly diagnosed and relapsed/refractory multiple myeloma who were receiving DVd-T reduced the incidence of VTEs without an increase in bleeding complications."
12/01/2005 - "To study the efficacy of daily low-dose aspirin (81 mg orally) in decreasing the incidence of venous thromboembolic events (VTEs) in patients with multiple myeloma receiving pegylated doxorubicin, vincristine, and decreased-frequency dexamethasone, plus thalidomide (DVd-T). "
|5.||Spinal Cord Injuries (Spinal Cord Injury)
|1.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|2.||Aspirin (Acetylsalicylic Acid)
|3.||Dalteparin (Dalteparin Sodium)
|2.||Drug Therapy (Chemotherapy)
|3.||Estrogen Replacement Therapy
|4.||Gynecologic Surgical Procedures (Gynecologic Surgery)
|5.||Length of Stay